Fig. 3

A Time-dependent MACE risk analysis, adjusted for admission HbA1c, 1-year HbA1c levels, age, hypertension, cigarette smoking, BMI, HDL, LDL-cholesterol levels, triglycerides, antithrombotic, and lipid-lowering and glucose-lowering therapies according to Cox regression analysis, along with the relative HR, 95% confidence interval, and P values for all the covariates used for the adjustment (table). B Time-dependent MACE risk analysis, adjusted for admission, age, hypertension, cigarette smoking, BMI, HDL LDL-cholesterol levels, triglycerides, antithrombotic, and lipid-lowering and glucose-lowering therapies according to Cox regression analysis, in never SGLT2i users (n = 118, 59%) and current SGLT2i users (N = 107, 60%) with good glycemic control (1-year HbA1c mean < 7%), along with the relative HR, 95% confidence interval, and P values for all the covariates used for the adjustment (table)